Aurora Cannabis - Kanada & die Legalisierung
Ich kann nur von eigenen Erfahrungen und Situationen bzw. manchen Gegebenheiten von Aktien-Spielchen reden sonst nichts...
Worauf ich mich freue : und da bin ich mir ziemlich sicher, dass wir hier bei Aurora einen Shortsqueeze sehen werden ( es gibt heftige und nicht so heftige) aber die Gegebenheiten sind GUT !
At the midyear point, the biggest losers were those who had shorted shares of Canada's Aurora Cannabis (ACB.T)(ACB.T), who were facing losses of $274 million, according to S3.
Das bedeutet trotz Kurs-Konso haben große Shortpositionen verluste noch immer in Verlusten und versuchen jetzt durch das Kurs-Sinken, Bestätigung in Ihren Position/Trades zu finden!
https://www.morningstar.com/news/marketwatch/...abis-stocks-will-fall
also heute sieht es ja nach der Trumpelei ganz gut aus, mal schauen was heute Nachmittag geht wenn die Amis und Canadier wieder dabei sind, sollte eigentlich gut werden
https://flashalert.me/...fourth-quarter-of-fiscal-2019-300896943.html
Aurora Cannabis Provides Corporate Update for the Fourth Quarter of Fiscal 2019
Aug 06, 2019, 07:00 ET
TSX |NYSE: ACB
EDMONTON , Aug. 6, 2019 /PRNewswire/ - Aurora Cannabis Inc. ("Aurora" or the "Company") (NYSE | TSX: ACB), the Canadian company defining the future of cannabis worldwide, today provided a corporate update on selected financial metrics for the fourth quarter of the Company's Fiscal 2019 ("Q4 2019") period ended June 30, 2019 . This reiteration of guidance and clarification of operations is intended to update our investors as Aurora continues to demonstrate leadership in transparency and disclosure as the industry navigates throughs periods of volatility. Full results will be published prior to September 15, 2019 , details for which will be provided in advance.
Based on a preliminary (unaudited) review, the Company anticipates net revenues for the quarter ended June 30, 2019 of between $100 million and $107 million (net of excise taxes), compared to $19.1 million in the period ended June 30, 2018 , and compared to $65.1 million for the previous quarter ended March 31, 2019 . Fiscal Q4 2019 net cannabis revenue is expected to be between $90 million and $95 million , with growth anticipated across all key business segments including medical, both Canadian and international, and consumer markets. The Company anticipates total net revenues for the fiscal year ended June 30, 2019 to be between $249 million - $256 million . The Company expects to report that production available for sale for Q4 2019 will be at the upper end of the range between 25,000 kg and 30,000 kg, ahead of previous guidance of 25,000 kgs.
These production and revenue estimates reflect strong delivery against corporate Key Performance Indicators ("KPIs"), the financial metrics the Company uses to evaluate the business on a day-to-day basis. The Company also expects to report sequential quarterly improvements in these KPIs, in particular: gross margins, kilograms of cannabis sold and cash costs per gram produced. The Company continues to track toward positive adjusted EBITDA, and in particular adjusted EBITDA from cannabis operations.
From the beginning, the Company's core philosophy of "purpose-built facilities" has focused on high quality cultivation of medical grade cannabis globally. This approach is validated by material growth in production and revenue and continued improvement in the above KPIs. Aurora's management team and Board of Directors continue to drive a culture rooted in quality, transparency, and regulatory compliance. Aurora has grown both organically and through acquisitions of companies with shared visions, and today this culture is ingrained in Aurora's over 2,500 employees across the globe.
"Our Q4 2019 guidance highlights Aurora's continued leadership," said Terry Booth , CEO of Aurora. "We set out to be best-in-class cultivators, and through carefully evaluated acquisitions, that vision continues to drive exceptional results today. We are the leader in cultivation capacity, production available for sale and revenues for cannabis in the Canadian medical and consumer markets. We continue to lead the build out of European and other international medical cannabis markets. Our success to date comes from a focus on quality, regulatory compliance, appropriate Board of Directors oversight, and delivering a profitable, low risk and sustainable business for our shareholders."
The preliminary estimated financial results and other data for the three months ended June 30, 2019 set forth above are subject to the completion of the Company's financial closing procedures. This data has been prepared by, and is the responsibility of, the Company's management. Aurora's independent registered public accounting firm, KPMG LLP, is in the process of performing year-end audit procedures with respect to the accompanying preliminary financial results and other data, and accordingly does not express an opinion or any other form of assurance with respect thereto. The Company currently expects that its final results of operations and other data will be consistent with the estimates set forth above, but such estimates are preliminary and Aurora's actual results of operations and other data could differ materially from these estimates due to the completion of its fiscal year-end audit procedures, final adjustments, and other developments that may arise between now and the time such annual audited consolidated financial statements for the twelve months ended June 30, 2019 are released.
The Company defines adjusted EBITDA as net income (loss) excluding interest income (expense), accretion, income taxes, depreciation, amortization, changes in fair value of inventory sold, changes in fair value of biological assets, share-based compensation, changes in fair value of financial instruments, gains and losses on deemed disposal, and non-cash impairment of equity investments, goodwill and intangible assets. Adjusted EBITDA from cannabis operations is defined as adjusted EBITDA for the Company's business units engaged in the production and sale of cannabis and legal derivatives thereof and excludes non-cannabis-related business units or operations.
Aurora Cannabis sees Q4 revenue net of excise taxes of C$100-C$107 million, up from C$19.1 million
Published: Aug 6, 2019 7:18 a.m. ET
https://www.marketwatch.com/story/...c191-million-2019-08-06?mod=bnbh
Der Umsatz soll den Angaben von Aurora Cannabis zufolge bei 100 bis 107 Millionen Kanadischen Dollar liegen. Im Vergleich zum entsprechenden Vorjahreszeitraum, als noch Einnahmen von 19,1 Millionen Kanadischen Dollar generiert wurden, entspricht dies mehr als einer Verfünffachung. Im gesamten Geschäftsjahr 2018/19 soll sich der Umsatz im Bereich von 249 bis 256 Millionen Kanadischen Dollar belaufen. Zudem erklärte Aurora Cannabis, weiteren gute Fortschritte auf dem Weg in Richtung eines positiven bereinigten EBIDTA zu machen. Die endgültigen Ergebnisse werden bis zum 15. September veröffentlicht.
Der Vorstandsvorsitzende von Aurora Cannabis, Terry Booth, zeigt sich dementsprechend zufrieden: „Unsere Guidance für das vierte Quartal unterstreicht, dass Aurora weiterhin führend ist. Wir sind ganz vorne, was die Produktionskapazität, die zum Verkauf angebotene Cannabis-Produktion und die Einnahmen für Cannabis in den kanadischen Medizin- und Verbrauchermärkten angeht. Wir haben uns zum Ziel gesetzt, die Besten zu sein. Und durch sorgfältig ausgewählte Akquisitionen führt dieser Leitsatz nun zu außergewöhnlichen Ergebnissen.“
Aurora wants a piece of THailand's medical cannabis market.. Look at Cam Battleys Twitter page.. https://mobile.twitter.com/cambattley?lang=en https://www.forbes.com/sites/andrebourque/2018/12/...ng/#657d97ce14b3
und hoffentlich gibt es bald mal ein paar gute News, obwohl das bei Cannopy nix genutzt hat
geschrieben... aber in naher Zukunft angestrebt.
Der Markt ist zur Zeit auf Angst programmiert. Selbst bei Aphria die schon schwarze Zahlen schreiben bleibt die Kurssteigerung nicht stabil.
Warten wir auf den Herbst wenn die Automobilindustrie nebst Zulieferer weiter Gewinnwarnungen aussprechen werden.... ???? Was soll die breite Masse dann kaufen???
...... C A N N A B I S ..... was sonst :))
Und egal wo zugekauft wird, die Woche drauf ist es tiefer.
Ich warte ab bis es wieder positiver aussieht.. Bin bei Aurora mit - 20 % ausreichend im Minus um NICHT WEITER IN DIE FALLENDE SÄGE ZU PACKEN:
Vielleicht sollten wir besser das Zeug rauchen, als die Aktien zu kaufen.
Bringt vermutlich bessere Stimmung ;-)
Aurora Cannabis Completes Hempco Food and Fibre Acquisition
https://ih.advfn.com/stock-market/NYSE/...06210-1591046686.1565076598
Hedge Fund Legend Jim Simons Pours Money Into Aurora Cannabis (ACB) and Aphria (APHA) Stocks
https://finance.yahoo.com/news/...JgkgrjcGPwtf7wnXQzhgILqg62vock6KPA1
2 Billionaires Just Bought Aurora Cannabis Stock
https://finance.yahoo.com/news/...s-just-bought-aurora-121500346.html
WELCOME TO BILLIONAIRES CLUB .....
Da hilft derzeit kein zukaufen, da es stetig weiter fällt.